Engaging Innovation | Friends of Cancer Research

Engaging Innovation

Featured Post

December 10, 2018

Friends of Cancer Research Annual Meeting 2018

This year’s Friends of Cancer Research (Friends) Annual Meeting started with a morning keynote by Anna Abram the Deputy Commissioner for Policy, Planning, Legislation and Analysis at the U.S. Food and Drug Administration (FDA). Abram discussed many different initiatives that have been led by Friends over the years including the...
More Posts

Recent Posts

No Results With Current Filter Choices

TMB Harmonization Working Group Fall Meeting

On September 13, 2018, Friends of Cancer Research (Friends) reconvened the TMB Harmonization Working Group, which consists of several stakeholders across all health sectors. Building from previous workshops hosted by Friends in the Fall of 2017 and the Spring of 2018, working group members:   Reviewed the findings of the first phase...

A Blueprint for Breakthrough: Research and Reimbursement in the Age of Precision Medicine

  Next-generation sequencing (NGS) is becoming a commonly used tool in cancer treatment. Transparency regarding the clinical performance and utility of different NGS-based tests available will aid in clinical decision-making and facilitate improvements in patient care.  The 7th Annual Blueprint for Breakthrough Forum, held by Friends of Cancer Research (Friends) and...

The FDA’s Budget: How Government Funds Safety and Efficacy

The U.S. Food and Drug Administration (FDA) fulfills its mission to protect and advance the public health by overseeing the development and approval of new medical products and ensuring that they are safe and effective for American consumers. When taking into consideration the full range of products the FDA oversees,...

The Future Use of Real-World Evidence

  Significant progress has been made in data collection efforts to support use of real-world evidence (RWE) in regulatory settings; however challenges remain, chiefly with combining, organizing, and analyzing data from various information sources. On July 10th, Friends of Cancer Research (Friends) hosted a meeting to present data from a pilot...

TMB Harmonization Working Group Meeting

On May 10, 2018, Friends of Cancer Research (Friends) convened stakeholders across all health sectors to assess current methods of measuring tumor mutational burden (TMB) and develop a consensus approach to the standardization of this biomarker. This roundtable built on a workshop hosted by Friends in the Fall of 2017,...

Molecularly Targeted Therapies in Pediatric Cancer

Robust drug development for pediatric cancers is critical to ensuring appropriate access to life-saving drugs and promoting innovation. As such, the FDA Reauthorization Act (FDARA) of 2017 included a provision requiring sponsors to investigate new molecularly targeted cancer drugs and biologics that are determined to be substantially relevant to the...

A Plea to Make Cancer Clinical Trials More Patient Friendly

Jim Omel is a myeloma patient and a cancer research advocate. He spoke at the 2017 Friends of Cancer Research Annual Meeting and was an author of the panel 2 whitepaper, Data Generation to Support Cross-Labeling of Indications for Combination Products. Below are his abridged remarks from the meeting. To...
first
prev
1
2
3
next
last
Back to Top